"Consumers and health care professionals will soon find updated labeling for extended-release and long-acting opioid pain relievers to help ensure their safe and appropriate use.
In addition to requiring new labeling on these prescript"...
Orphenadrine citrate is a cen-trallyacting(brain stem) compound which in animals selectively blocks facilitatory functions of the reticularformation. Orphenadrine does not produce myoneural block, nor does it affect crossed extensor reflexes. Orphenadrine prevents nicotine-induced convulsions but not those pro-ducedby strychnine.
Chronic administration of Or-phenadrine Citrate, Aspirin and Caffeine to dogsandratshas revealed no drug-related toxi-city. Nobloodorurine changes were observed, nor were there any macroscopic or microscopic pathological changes detected. Extensive experience with combinations containing aspirin and caffeine hasestablished them as safe agents. The addition oforphen-adrine citrate does not alter the toxicity of aspirin and caffeine.
Last reviewed on RxList: 12/17/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Orphengesic Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.